Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Brii Bio Completes $155 Million Financing for Anti-infective/CNS Drugs

publication date: Mar 23, 2021

Brii Biosciences, a Shanghai-US company developing anti-infectives and CNS products for China, completed a $155 million Series C financing. Brii develops its own anti-infective candidates for drug-resistant and otherwise difficult-to-treat pathogens. and it in-licenses other programs. Over the past year, several reports have surfaced that Brii is planning a Hong Kong IPO. The C round was led by Invesco Developing Markets Fund with additional funding from GIC and an unnamed global fund. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital